# Cube Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cube-biotech

- Industry: Biotechnology
- Headquarters: Monheim, Germany
- Website: www.cube-biotech.com
- Latest round: Series A (Dec 13, 2012)
- Investors on record: 1

## About

Cube Biotech GmbH specializes in advanced protein solutions by focusing on the stabilization and purification of membrane proteins, benefiting research and pharmaceutical sectors with innovative technologies and services.Cube Biotech GmbH, founded in 2012, is based in Monheim, Germany. The company specializes in providing solutions related to membrane proteins. Frank Schaefer, the founder, has been pivotal in establishing the company's strategic direction. In November 2021, ArchiMed acquired a majority stake in Cube Biotech from Creathor Ventures, strengthening its operational framework. The company has completed a total of 2 deals, with the most recent in November 2021.Cube Biotech specializes in advanced protein-related solutions, focusing on the stabilization and purification of membrane proteins. Their core offerings include the flagship NativeMP™ Technology, designed to enhance the yield and functionality of membrane proteins by stabilizing them in their native environments. Additionally, the company provides a comprehensive suite of services such as protein purification, proteomics, and the production of cell-free lysates. These products cater primarily to research institutions, pharmaceutical companies, and biotechnology firms engaged in drug development and protein research, addressing critical challenges in protein handling and analysis. Cube Biotech serves a diverse range of geographical markets, including North America, Europe, and parts of Asia.Cube Biotech's revenue model is structured around direct sales and customized service agreements within the B2B sector, primarily targeting research and development entities in the life sciences. Transactions typically involve clients ordering specific products such as the NativeMP™ Technology along with additional protein purification services tailored to their unique research needs. Pricing for products and services is generally structured around project scopes and specific client requirements, ensuring that each transaction aligns with the individual goals of the customer. The company also engages in partnerships with institutions for collaborative research projects, further enhancing their revenue through tailored service offerings and solutions.Cube Biotech is focused on enhancing its product portfolio with upcoming innovations in protein stabilization technologies. The company aims to expand its presence in new markets, specifically targeting regions in Asia by the end of 2023. The recent acquisition by ArchiMed in November 2021 will support these initiatives, providing necessary resources for research and development as well as market penetration strategies.

## Funding rounds

- Series A, Dec 13, 2012 — Creathor Ventures

## Investors

- Creathor Ventures (https://capitalatlas.ai/funds/creathor-ventures) — Series A